

## Research Article

# The $\alpha 7$ Nicotinic Acetylcholine Receptor: a Key Molecule in Post-COVID Syndrome?

Maryna Skok<sup>1</sup>

1. Palladin Institute of Biochemistry, Kyiv, Ukraine

Post Acute Sequelae of COVID-19 (PASC) appears with a considerable delay after recovery from the acute phase and lasts for months or even years. It includes injuries of multiple organs, as well as cognitive impairment, fatigue, disordered sleep and memory loss. In spite of substantial efforts undertaken to understand the nature of this pathology the mechanisms of its development remain unclear and no efficient treatment has been suggested. The present review provides evidence indicating the important role of  $\alpha 7$  nicotinic acetylcholine receptors in COVID19 pathogenesis and PASC development and suggests the involvement of immune mechanisms stimulated by SARS-Cov-2 S-protein fragment 674-685 possessing homology with  $\alpha 7$ -specific ligands. It is hypothesized that delayed PASC symptoms can be stimulated by  $\alpha 7$ -specific antibodies of anti-idiotypic origin; consequently, the therapeutic approaches to cure or prevent PASC development should include measures to both neutralize such antibodies and additionally stimulate  $\alpha 7$  nicotinic acetylcholine receptors.

COVID-19 has taken millions of lives throughout the world since 2019. The quarantine measures and anti-virus vaccines allowed slowing the spread of infection. However, people who have recovered from the acute disease often continue to suffer from its consequences. This state was called Post Acute Sequelae of COVID-19 (PASC), “post-COVID” or “long COVID”. The PASC is a debilitating state which appears after the acute phase cessation, sometimes with a considerable delay of weeks or even months after recovery, and lasts for months or even years. It is a multi-organ pathology including injuries of heart, lungs, kidney, liver, spleen, pancreas, gastrointestinal tract, as well as cognitive impairment, fatigue, disordered sleep and memory loss (reviewed in Davis et al., 2023). In spite of substantial efforts undertaken to understand the nature of this pathology the mechanisms of its development

remain unclear and no efficient treatment has been suggested. The present review provides evidence indicating the important role of cholinergic mechanisms, in particular, those mediated by  $\alpha 7$  nicotinic acetylcholine receptors ( $\alpha 7$  nAChRs), the mechanisms of their impairment in PASC pathogenesis and suggests the ways of treatment.

The  $\alpha 7$  nAChRs belong to the family of nAChRs. The members of this family were at first characterized as ligand-gated ion channels mediating fast synaptic transmission in neuro-muscular junctions and autonomic ganglia (Lindstrom, 1996). Further, it was discovered that nAChRs are also present in many non-excitabile cells and are involved in regulating cell survival, adhesion and proliferation, as well as neurotransmitter and cytokine release (reviewed in Skok, 2022a). Structurally, they are pentameric transmembrane proteins composed of 10 types of  $\alpha$  subunits ( $\alpha 1$  to  $\alpha 10$ ) and 4 types of  $\beta$  subunits ( $\beta 1$  to  $\beta 4$ ) combined in several established combinations. The muscle nAChRs contain  $\gamma$ ,  $\delta$  and  $\epsilon$  subunits in addition to  $\alpha 1$  and  $\beta 1$  subunits. (Lindstrom, 1996). The autonomic ganglia contain mainly  $\alpha 3(\alpha 5)\beta 4$  nAChRs, while  $\alpha 4\beta 2$  nAChRs are mainly expressed in the brain (Gotti et al., 2009). The nAChRs composed of  $\alpha 7$  subunits, either as homopentamers, or heteropentamers with  $\beta 2$  subunits, are the most ubiquitous: they are found in the brain and autonomic ganglia and in many, if not all, non-excitabile cells; they were also found in mitochondria and cell nuclei outer membranes (Kawashima et al., 2015; Skok, 2022b; Kalashnyk et al., 2023). They can function/signal both ionotropically and metabotropically; however, their ion channel is quickly desensitized; therefore, most probably, their functions are mainly mediated in ion-independent manner, through conformational/allosteric movements affecting neighboring receptors and signaling molecules (King et al., 2015).

One of the most widely studied functions of  $\alpha 7$  nAChRs is their ability to control the release of pro-inflammatory cytokines by the cells of monocyte origin and in such a way to attenuate inflammation (De Jonge and Ulloa, 2007). Acetylcholine released from the vagus nerve endings was shown to affect  $\alpha 7$  nAChRs on peritoneal macrophages (Wang et al., 2003). The classical symptom of COVID-19 is hyperinflammation caused by excessive release of pro-inflammatory cytokines (the “cytokine storm”). Therefore, the  $\alpha 7$  nAChRs, known to be involved in regulating inflammation, appeared in the center of attention. SARS-Cov-2 infection was found to be accompanied by vagus nerve neuropathy (Moyano et al, 2021) and impaired vagal activity was found in long-Covid patients (Acanfora et al., 2022). It was suggested that SARS-CoV-2 induces vagus nerve inflammation followed by autonomic dysfunction which contributes to critical disease courses and might contribute to dysautonomia

observed in long COVID (Woo et al., 2023). Cholinergic disfunction upon COVID-19 has already been discussed (Nadwa et al., 2023).

The  $\alpha 7$  nAChRs were also shown to control neuroinflammation in the brain and in such a way influence learning and memory. In our experiments, mice treated with bacterial lipopolysaccharide (LPS) developed neuroinflammation and demonstrated decreased levels of  $\alpha 7$  nAChRs in the brain and impaired episodic memory (Lykhmus et al., 2015). Injections of  $\alpha 7$ -selective agonist PNU282987 prevented both  $\alpha 7$  nAChR decrease and memory decline under the effect of LPS (Lykhmus et al., 2020). Neuroinflammation is considered to accompany and even provoke neurodegeneration in Alzheimer and Parkinson diseases (Onyango et al., 2021). In our experiments, injections of PNU282987 improved memory of transgenic APP43PS1 mice, an established model of Alzheimer disease (Lykhmus et al., in preparation). COVID-19 neuropathology was shown to include Alzheimer-like features (Reiken et al., 2022). COVID-19 patients seem to be more prone to developing Alzheimer disease and Alzheimer patients could be more susceptible to severe COVID-19 (Ciassio et al., 2021). The brain metabolite kynurenic acid inhibits  $\alpha 7$  nicotinic receptor activity (Hilmas et al., 2001). Activation of the kynurenine pathway has been identified in long COVID, and is associated with cognitive impairment (Cysique et al., 2022).

The data provided above clearly indicate that SARS-Cov-2 infection affects  $\alpha 7$  nAChRs. The mechanism of such influence was first suggested in the paper of Changeux et al., 2020, where it was shown that the fragment 674-685 of SARS-Cov-2 spike protein possesses structural homology with known ligands of  $\alpha 7$  nAChRs:  $\alpha$ -cobratoxin,  $\alpha$ -bungarotoxin and rabies virus; the latter penetrates infected cells through  $\alpha 7$  nAChR. Structural studies confirmed this idea and showed that peptide Y674-R685 penetrates deeply into the binding pocket of  $\alpha 7$  nAChR and forms interactions with aromatic residues of adjacent loops B and C (Oliveira et al., 2021). Electrophysiological experiments demonstrated that this peptide exerts a dual effect on  $\alpha 7$ . It activates  $\alpha 7$  nAChRs in the presence of positive allosteric modulators but decreases the  $\alpha 7$  channel activity elicited by acetylcholine (Chrestia et al., 2022), possibly, because of the competition for acetylcholine-binding site. In our experiments, peptide 674-685 competed with  $\alpha 7$ -specific antibodies for the binding to  $\alpha 7$ (179-190) fragment and attenuated cytochrome *c* release from mitochondria stimulated with  $Ca^{2+}$  similarly to other  $\alpha 7$ -selective ligands including  $\alpha 7$ -binding fragment of  $\alpha$ -cobratoxin (Kalashnyk et al., 2021). We suggested that when the virus penetrates the infected cell and its protein part is cleaved by cellular

proteases, fragment 674-685 can influence mitochondria and support the cell viability during the period necessary for virus replication by inhibiting mitochondria apoptosis pathway.

Fragment 674-685 contains a PRRA motif, a four-residue insertion not found in other SARS-like coronaviruses (Oliveira et al., 2021). This positively charged cluster of amino acids can mimic the quaternary nitrogen of choline underlying the SARS(674-685) interaction with  $\alpha 7$  nAChR. This fragment is naked upon the virus spike protein cleavage by cellular protease and is considered important for the binding to neuropilin that favors the virus penetration into the cell (Abebe et al., 2021). The main gate for the SARS-Cov-2 entry into the cell is considered to be angiotensin-converting enzyme-2 (ACE-2) receptor (Wang et al., 2020). We have found that ACE-2 expressed in astrocytoma U373 cells interacts with  $\alpha 7$  nAChR because their complex was identified in U373 cell lysates by Sandwich ELISA (Lykhmus et al., submitted). Therefore, affecting  $\alpha 7$  nAChR can interfere with (prevent) virus penetration into the cell. However, this idea needs experimental confirmation.

Interestingly, SARS(674-685) peptide was shown to interact not only with  $\alpha 7$  nAChRs, but also with  $\alpha 4\beta 2$  and muscle ( $\alpha 1\beta 1\gamma\delta$ ) nAChR subtypes; however, the mode of binding was somehow different from that with  $\alpha 7$  nAChR and was similar to the binding of antagonists (Oliveira et al., 2021). Possibly this finding can explain why COVID-19 infection increases the risk of new-onset myasthenia gravis, a disease affecting muscular nAChRs (Tugasworo et al., 2022).

Another line of evidence demonstrates that SARS-Cov-2 S-protein possesses one more site capable to bind nAChRs, namely fragment 381-386, also with homology to a sequence of a snake venom toxin (Farsalinos et al., 2020; Lagoumintzis et al., 2021).

The data on direct interaction of SARS-Cov-2 with nAChRs allowed hypothesizing that nicotine and other cholinergic agonists can have a protective role. The data on the role of smoking upon COVID-19 are contradictory: some of them indicate that smoking people are rare among patients with severe COVID; others show that smoking aggravates the infection (Shastri et al., 2021). However, adding AChE inhibitor to the treatment protocol (that increases the level of acetylcholine and stimulates nAChR activation) is beneficial (Foster et al., 2023). We have found that another re-purposed drug, hydroxyurea, which appeared to be very efficient in treating patients with severe COVID (Foster et al., 2021), can bind  $\alpha 7$  nAChR and, in fact, behaves as a positive allosteric modulator of this nAChR subtype (Lykhmus et al., submitted).

Taken together, the data presented clearly demonstrate that  $\alpha 7$  nAChRs are involved in pathogenesis of COVID-19 and that SARS-Cov-2 can directly affect this nAChR subtype. Such interaction can

influence both virus penetration into the cell and the inflammatory process stimulated by infection. Therefore, stimulating  $\alpha 7$  nAChRs by either endogenous acetylcholine or externally added agonist/allosteric modulator can be beneficial for treatment of COVID patients. However, the situation with post-COVID syndrome (PASC) is not so clear. This state develops weeks or even months after recovery from the acute phase of infection and is hardly to be explained by continuous virus persistence in the organism. On the other hand, such a delay indicates that certain immunological mechanisms, which develop slowly, can be involved.

We immunized mice with SARS(674-685) peptide and observed an inflammatory response and a dramatic decrease of their episodic memory, which could be prevented by injections of choline, an  $\alpha 7$  nAChR agonist. The brains of immunized mice contained decreased amounts of  $\alpha 7$  nAChR compared to those of non-immunized mice; choline injections restored them to normal levels and hydroxyurea injections decreased IL- $1\beta$  levels in the brain (Lykhmus et al., 2022 and submitted). Memory loss could be transferred to non-immunized mice by injections of immunoglobulins purified from the blood sera of immunized mice (Lykhmus et al., 2022). Analysis of these immunoglobulins demonstrated that they contain SARS(674-685)-specific antibodies (both IgM and IgG), as well as  $\alpha 7(179-190)$ -specific antibodies (mainly IgM) (Lykhmus et al., 2022 and submitted). The  $\alpha 7(179-190)$ -specific antibodies were previously shown to cause inflammatory reaction, to decrease  $\alpha 7$  nAChR content in the brain and to impair memory (Lykhmus et al., 2015). Therefore, these are  $\alpha 7(179-190)$ -specific antibodies which could be a pathogenic factor causing memory loss in SARS(674-685)-immunized mice. The working hypothesis to explain the appearance of  $\alpha 7(179-190)$ -specific antibodies in SARS(674-685)-immunized mice is the involvement of idiotype-anti-idiotype network. Anti-idiotypic antibodies are regarded as “internal image” of the antigen stimulating primary (idiotypic) antibody production (Jerne and Cocteau, 1984). In our case, the antigen is SARS(674-685), which binds to  $\alpha 7(179-190)$ ; therefore, anti-idiotypic antibody should also bind  $\alpha 7(179-190)$  that is actually observed. Anti-idiotypic antibodies are produced in response to idiotypic ones; therefore, their appearance is delayed compared to primary idiotypes. Indeed, we observed IgM anti- $\alpha 7(179-190)$  after second immunization with SARS(674-685) when both IgM and IgG anti-SARS(674-685) were already present in the blood. The  $\alpha 7$ -specific anti-idiotypic antibodies can explain the pathogenic symptoms of PASC, which appear quite long after the acute phase of COVID.

Auto-anti-idiotypic antibodies are generated during anti-viral immune response (Jiang et al., 2003; Tzioufas and Routsias, 2010) that supports our hypothesis. Moreover, anti-idiotypic vaccines for a

number of viruses including reovirus, rabies virus, murine mammary tumor virus (MMTV), murine leukemia virus, hepatitis B virus (HBV) and human immunodeficiency virus (HIV) have been developed (Naveed et al, 2018).

We found both SARS(674-685)-specific and  $\alpha 7$ (179-190)-specific antibodies in the blood of people who experienced COVID-19 two to six months ago; many of them complained for the cognitive impairment including memory loss.

The  $\alpha 7$  nAChRs are expressed in many organs and tissues. Therefore, the presence of anti-idiotypic  $\alpha 7$ -specific antibodies can explain multi-organ symptoms of PASC. In contrast to the live virus, such antibodies can persist for a long time; moreover, their generation is stimulated by SARS(674-685)-specific antibodies. In fact, this is a self-supporting system where idiotypic and anti-idiotypic antibodies stimulate each other; as a result pathogenic consequences of their interaction with cells and tissues can persist for a long time that is actually observed.

Assuming that  $\alpha 7$  nAChRs are the key targets for pathogenic antibodies, the most evident therapeutic solution to overcome their influence is the use of  $\alpha 7$ -selective agonists, which stimulate  $\alpha 7$  nAChR signaling and can prevent  $\alpha 7$ (179-190)-specific antibody binding (because  $\alpha 7$ (179-190) fragment contains the elements of agonist binding site). AChE inhibitors can also help by increasing the endogenous acetylcholine levels. The less evident and advanced solution may be the injections of protein-conjugated  $\alpha 7$ (179-190), which should neutralize  $\alpha 7$ (179-190)-specific antibodies and favor their elimination that can both prevent their pathogenic effects in cells and interrupt the idiotype-anti-idiotype loop.

In conclusion, the available data indicate that (1)  $\alpha 7$  nAChRs play a key role in COVID19 pathogenesis and PASC development; (2) PASC symptoms can be stimulated by  $\alpha 7$ -specific antibodies of anti-idiotypic origin; and (3) the therapeutic approaches to cure or prevent PASC development should include measures to both neutralize such antibodies and additionally stimulate  $\alpha 7$  nAChRs.

## References

- Abebe Chekol E., Mengie Ayele T., Tilahun Muche Z., Asmamaw Dejenie T. (2021), Neuropilin1: A novel entry factor for SARS-CoV-2 infection and a potential therapeutic target, *Biologics*. 15, 143-152. <https://doi.org/10.2147/BTT.S307352>

- Acanfora D, Nolano M, Acanfora C, Colella C, Provitera V, Caporaso G, Rodolico GR, Bortone AS, Galasso G, Casucci G. (2022), Impaired Vagal Activity in Long-COVID-19 Patients. *Viruses*.14(5), 1035-1040. doi: 10.3390/v14051035.
- Changeux, J.P., Amoura, Z., Rey, F.A., Miyara, M. (2020), A nicotinic hypothesis for Covid-19 with preventive and therapeutic implications. *C. R. Biol.* 343(1), 33-39. doi:10.5802/crbio.8
- Chrestia JF, Oliveira AS, Mulholland AJ, Gallagher T, Bermúdez I, Bouzat C. (2022), A Functional Interaction Between Y674-R685 Region of the SARS-CoV-2 Spike Protein and the Human  $\alpha 7$  Nicotinic Receptor. *Mol Neurobiol.* 59(10), 6076-6090. doi: 10.1007/s12035-022-02947-8.
- Ciaccio M, Lo Sasso B, Scazzone C, Gambino CM, Ciaccio AM, Bivona G, Piccoli T, Giglio RV, Agnello L. (2021), COVID-19 and Alzheimer's Disease. *Brain Sci.* 11(3), 305. doi: 10.3390/brainsci11030305.
- Cysique, L. A., Jakabek D., Bracken S.G. et al. (2022) Post-acute COVID-19 cognitive impairment and decline uniquely associate with kynurenine pathway activation: a longitudinal observational study. Preprint at *medRxiv* 10.1101/2022.06.07.22276020
- Davis H.E, McCorkell L., Vogel J.M., Topol E.J. (2023), Long COVID: major findings, mechanisms and recommendations. *Nat Rev Microbiol.* 21(3), 133-146. doi: 10.1038/s41579-022-00846-2.
- De Jonge, W.J., Ulloa, L. (2007), The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation. *Br. J. Pharmacol.* 151, 915-929. doi:10.1038/sj.bjp.0707264.
- Farsalinos K., E. Eliopoulos, D.D. Leonidas, G.E. Papadopoulos, S. Tzartos, K. Poulas, (2020), Nicotinic cholinergic system and COVID-19: in silico identification of an interaction between SARS-CoV-2 and nicotinic receptors with potential therapeutic targeting implications, *Int. J. Mol. Sci.* 21(16), 5807. <https://doi.org/10.3390/ijms21165807>
- Foster, M.R.B., Hijazi, A.A., Opoku, R., Varghese, P., Li, C. (2021). The Use of Hydroxyurea in the Treatment of COVID-19. *J. Crit. Care Med. (Targu Mures).* 7(4), 312-317. doi: 10.2478/jccm-2021-0019.
- Foster, M.R.B., Hijazi, A.A., Sullivan, R.C., Opoku, R. (2023). Hydroxyurea and pyridostigmine repurposed for treating Covid-19 multi-systems dysfunctions. *AIMS Medical Science.* 10(2), 118-129. doi:10.3934/medsci.2023010
- Gotti, C., Clementi, F., Fornari, A., Gaimarri, A., Guiducci, S., Manfredi, I., Moretti, M., Pedrazzi, P., Pucci, L., Zoli, M. (2009). Structural and functional diversity of native brain neuronal nicotinic receptors, *Biochem. Pharmacol.* 78 703-711. <https://doi.org/10.1016/j.bcp.2009.05.024>
- Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX. (2001), The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7

nicotinic receptor expression: physiopathological implications. *J Neurosci.* 21(19),7463-73. doi:10.1523/JNEUROSCI.21-19-07463.2001.

- Jerne K., Cocteau J., (1984), Idiotypic networks and other preconceived ideas. *Immunol. Rev.* 79, 5–24. <https://doi.org/10.1111/j.1600-065x.1984.tb00484.x>
- Jiang Z., Zhou E.M., Ameri-Mahabadi M., Zimmerman J.J., Platt K.B. (2003), Identification and characterization of auto-anti-idiotypic antibodies specific for antibodies against porcine reproductive and respiratory syndrome virus envelope glycoprotein (GP5). *Vet. Immunol. Immunopathol.* 92(3-4), 125-135. [https://doi.org/10.1016/s0165-2427\(03\)00022-9](https://doi.org/10.1016/s0165-2427(03)00022-9)
- Kalashnyk, O., Lykhmus, O., Izmailov, M., Koval, L., Komisarenko, S., Skok, M. (2021), SARS-Cov-2 spike protein fragment 674-685 protects mitochondria from releasing cytochrome c in response to apoptogenic influence. *Biochem. Biophys. Res. Commun.*, 561, 14-18. doi:10.1016/j.bbrc.2021.05.018.
- Kalashnyk, O., Lykhmus, O., Koval, L., Uspenska, K., Obolenskaya, M., Chernyshov, V., Komisarenko, S., Skok, M. (2023),  $\alpha 7$  Nicotinic acetylcholine receptors regulate translocation of HIF-1 $\alpha$  to the cell nucleus and mitochondria upon hypoxia. *Biochem. Biophys. Research Com.* 657, 35-42. doi:org/10.1016/j.bbrc.2023.03.021.
- Kawashima, K., Fujii, T., Moriwaki, Y., Misawa, H., Horiguchi, K. (2015). Non-neuronal cholinergic system in regulation of immune function with a focus on  $\alpha 7$  nAChRs. *Int. Immunopharmacol.* 29, 127-134. doi:10.1016/j.intimp.2015.04.015
- King, J.R., Nordman, J.C., Bridges, S.P., Lin, M.K., Kabbani, N. (2015). Identification and Characterization of a G Protein-binding Cluster in  $\alpha 7$  Nicotinic Acetylcholine Receptors. *J. Biol. Chem.* 290, 20060-20070. doi:10.1074/jbc.M115.647040.
- Lagoumintzis G, Chasapis CT, Alexandris N, Kouretas D, Tzartos S, Eliopoulos E, Farsalinos K, Poulas K. (2021), Nicotinic cholinergic system and COVID-19: In silico identification of interactions between  $\alpha 7$  nicotinic acetylcholine receptor and the cryptic epitopes of SARS-Co-V and SARS-CoV-2 Spike glycoproteins. *Food Chem Toxicol.* 149,112009. doi: 10.1016/j.fct.2021.112009.
- Lindstrom, J., (1996). Neuronal nicotinic acetylcholine receptors, in: T. Narahashi (Ed.), *Ion Channels*, Plenum Press, New York. Vol. 4, pp. 377-390.
- Lykhmus, O., Kalashnyk, O., Koval, L., Krynina, O., Komisarenko, S., Skok, M. (2022). Immunization with 674-685 fragment of SARS-Cov-2 spike protein induces neuroinflammation and impairs episodic memory of mice. *Biochem. and Biophys. Res. Commun.* 622, 57-63. [doi:10.1016/j.bbrc.2022.07.016](https://doi.org/10.1016/j.bbrc.2022.07.016).



- Lykhmus, O.Yu., Kalashnyk, O.M., Uspenska, K.R., Skok, M.V. (2020). Positive allosteric modulation of  $\alpha 7$  nicotinic acetylcholine receptors transiently improves memory but aggravates inflammation in LPS-treated mice. *Front. Ageing Neurosci*, 11, article 359, doi: 10.3389/fnagi.2019.00359
- Lykhmus, O., Voytenko, L., Koval, L., Mykhalskiy, S., Kholin, V., Peschana, K., Zouridakis, M., Tzartos, S., Komisarenko, S., Skok, M. (2015).  $\alpha 7$  Nicotinic Acetylcholine Receptor-Specific Antibody Induces Inflammation And Amyloid  $\beta_{42}$  Accumulation In The Mouse Brain To Impair Memory. *PLoS ONE*. 0(3):e0122706. doi:10.1371/journal.pone.0122706.
- Moyano A JR, Mejía Torres S, Espinosa J. (2021), Vagus nerve neuropathy related to SARS COV-2 infection. *IDCases*.;26:e01242. doi: 10.1016/j.idcr.2021.e01242.
- Nadwa EH, Al-Kuraishy HM, Al-Gareeb AI, Elekhrawy E, Albogami SM, Alorabi M, Batiha GE, De Waard M. (2023) Cholinergic dysfunction in COVID-19: frantic search and hoping for the best. *Naunyn Schmiedebergs Arch Pharmacol*. 396(3):453-468. doi: 10.1007/s00210-022-02346-9.
- Naveed A., Rahman S.U., Arshad M.I., Sharif M., Saleem A., Aslam B. (2018), Recapitulation of the anti-Idiotypic antibodies as vaccine candidate. *Trans. Med. Commun.* 3, 1. <https://doi.org/10.1186/s41231-018-0021-4>.
- Oliveira ASF, Ibarra AA, Bermudez I, Casalino L, Gaieb Z, Shoemark DK, Gallagher T, Sessions RB, Amaro RE, Mulholland AJ. (2021), A potential interaction between the SARS-CoV-2 spike protein and nicotinic acetylcholine receptors. *Biophys J*. 120(6), 983-993. doi:10.1016/j.bpj.2021.01.037
- Onyango IG, Jauregui GV, Čarná M, Bennett JP Jr., Stokin GB. (2021), Neuroinflammation in Alzheimer's Disease. *Biomedicines*.; 9(5):524. <https://doi.org/10.3390/biomedicines9050524>.
- Reiken S, Sittenfeld L, Dridi H, Liu Y, Liu X, Marks AR. (2022) Alzheimer's-like signaling in brains of COVID-19 patients. *Alzheimers Dement*. 18(5), 955-965. doi: 10.1002/alz.12558
- Shastri MD, Shukla SD, Chong WC, Kc R, Dua K, Patel RP, Peterson GM, O'Toole RF. (2021) Smoking and COVID-19: What we know so far. *Respir Med*. 176, 106237. doi: 10.1016/j.rmed.2020.106237.
- Skok, M. (2022a). Universal nature of cholinergic regulation demonstrated with nicotinic acetylcholine receptors. *BBA Advances*. 2, 100061 [doi:10.1016/j.bbadv.2022.100061](https://doi.org/10.1016/j.bbadv.2022.100061)
- Skok, M. (2022b). Mitochondrial nicotinic acetylcholine receptors: mechanisms of functioning and biological significance (review). *Int. J. Biochem. Cell Biol*. 143, 106138. doi: 10.1016/j.biocel.2021.106138.

- Tugasworo D, Kurnianto A, Retnaningsih, Andhitara Y, Ardhini R, Budiman J. (2022), The relationship between myasthenia gravis and COVID-19: a systematic review. *Egypt J Neurol Psychiatr Neurosurg.*58(1), 83. doi: 10.1186/s41983-022-00516-3.
- Tzioufas A.G., Routsias J.G. (2010), Idiotype, anti-idiotype network of autoantibodies: Pathogenetic considerations and clinical application. *Autoimmun. Rev.* 9(9), 631–633. <https://doi.org/10.1016/j.autrev.2010.05.013>.
- Wang, H., Yu, M., Ochani, M., Amella, C.A., Tanovic, M., Susarla, S. et al. (2003) Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. *Nature* 421(6921), 384–388.
- Wang, Q, Zhang, Y., Wu, L., Niu, S., Song, C., Zhang, Z., Guangwen, L., Qiao, C., Hu, Y., Yuen, K.Y., Wang, Q., Zhou. H., Yan, J., Qi, J. (2020). Structural and functional basis of SARS-CoV-2 entry by using human ACE2, *Cell* 181(4), 894–904, e9 doi: 10.1016/j.cell.2020.03.045.
- Woo MS, Shafiq M, Fitzek A, Dottermusch M, Altmeppen H, Mohammadi B, Mayer C, Bal LC, Raich L, Matschke J, Krasemann S, Pfefferle S, Brehm TT, Lütgehetmann M, Schädler J, Addo MM, Schulze Zur Wiesch J, Ondruschka B, Friese MA, Glatzel M. (2023), Vagus nerve inflammation contributes to dysautonomia in COVID-19. *Acta Neuropathol.* 146(3), 387-394. doi: 10.1007/s00401-023-02612-x.

## Declarations

**Funding:** No specific funding was received for this work.

**Potential competing interests:** No potential competing interests to declare.